

PRESS RELEASE - FOR IMMEDIATE RELEASE

IntegraGen - First-Half 2010 Results

- **Steady growth in revenue**
- **Stringent cost management**
- **Launch of the ARISk test in the US, the first genetic risk assessment for autism in children with affected sibling**

EVRY, TUESDAY, OCTOBER 12, 2010 - **IntegraGen**, the French molecular diagnostic company, announced today its results for the first half of fiscal year 2010. Accounts for the first half-year of 2010 were reviewed by the Board of Directors held on September 30th, 2010.

KEY HIGHLIGHTS - in Thousand euros	H1 2010	2009
Sales	1 485	2 813
Operating result	(1 335)	(3 244)
Net result	(1 194)	(2 603)
Cash available at end of period	7 576	1 542

Bernard Courtieu, Chief Executive Officer declared: *"Results for the first half of 2010 are in line with our objectives. They show the robustness of our genomic services activity and its ability to be the reference provider of leading edge technology. Meanwhile, our partner in the US Transgenomic (OTC BB: TBIO.OB) has launched on the US market the ARISk test, the first genetic test that assesses the risk of autism in children who have older siblings diagnosed with an autism spectrum disorder. Transgenomic was able to develop and validate the test and to add it to its portfolio of tests available to clinicians by June, which will allow IntegraGen to start receive proceeds from the licensing deal from the second half of the year".*

KEY HIGHLIGHTS

▪ **Autism : Launch of ARISk in the US**

Last February, IntegraGen signed an exclusive licensing agreement with Transgenomic Inc. This agreement has allowed Transgenomic to develop and commercialize the first genetic risk assessment test assessing the risk of autism in children who have older siblings diagnosed with an autism spectrum disorder. Transgenomic has developed this test within its CAP accredited CLIA certified laboratory, and launched the test commercially in June 2010.

▪ **Oncology**

IntegraGen, has launched a project in the field of Oncology in november 2009, with the objective of creating a reference center for the validation of biomarkers in oncology.

Two biomarkers will be launched by 2013 via this platform in the field of hepatocellular carcinoma and metastatic colorectal cancer.

This project received the Medicen Label in 2010 as cooperative R&D.

FINANCIALS

▪ **Income Statement**

Sales for H1 2010 were of 1.485 million euros. The company did not provide consolidated numbers for H1 2009 and this figure is to be compared with 1.127 million euro of invoices for the comparable period in H1 2009, representing a 32% growth.

Growth was generated by all services lines, with high throughput sequencing experiencing the highest growth rate and demonstrating very high demand for this leading edge complex technology. H1 2010 revenue are equivalent to 53% of 2009 total year revenue.

Operational result showed a loss of 1.3 million euros for H1 2010, a significant improvement compared to the loss of 3.2 million of the whole year 2009. This improvement in profitability was due to a tight control of costs of reagents as well as external charges.

Net loss for the period were of 1.2 million euros, to be compared to a net loss of 2.6 million euro for the whole year 2009. Worth noting, during H1 2010 the net result was impacted by an exceptional charge of 0.4 million euro related to the IPO expenses.

▪ **Balance sheet**

As of June 30th, 2010 IntegraGen cash and cash equivalents were 7.6 million euros as compared to 1.5 million euros for the period ended on 31st of December 2009. This significant increase is related to the private placement held in June 2010 that was followed by the listing of the Company on the Alternext market.

EXPECTATIONS

IntegraGen confirms its objective of reaching profitability by 2013.

INTEGRAGEN

Located in the Evry Genopole and created in 2000, IntegraGen is dedicated to research and identification of genetic biomarkers, development and distribution of molecular diagnostic products and services. IntegraGen's strategy is to allow clinical practitioners to use new diagnostic tools, improving patients' care, thanks to applications and Intellectual Property concentrated in two fields: autism and oncology. IntegraGen's Business Genomic Services Unit also provides state of the art genomic services and sequencing for scientific research.

IntegraGen is listed on Alternext of NYSE Euronext Paris (Isin: FR0010908723 - Code: ALINT).

Website: www.integragen.com

CONTACTS

INTEGRAGEN

Bernard Courtieu
Chief Executive Officer
Contact@integragen.com
Phone: +33 (0)1 60 91 09 00

Patrick Court
Chief Financial Officer
Contact@integragen.com
Phone: +33 (0)1 60 91 09 09

LT VALUE

Investor Relations

Nancy Levain / Maryline Jarnoux-Sorin
nancy.levain@ltvalue.com / maryline.jarnoux-sorin@ltvalue.com
Phone: +33 (0)1 44 50 39 30 - +33 (0)6 72 28 91 44

Media Relations

Antoinette Darpy
antoinette.darpy@ltvalue.com
Phone: +33 (0)6 72 95 07 92

CONSOLIDATED INCOME STATEMENT

CONSOLIDATED INCOME STATEMENT In €	30-06-2010	31-12-2009
Sales	1 485 178	2 813 085
Other Income	87 885	94 000
Revenue	1 573 063	2 907 085
Purchases of goods and external services	1 774 902	4 019 872
Indirect taxes	33 788	97 397
Wages and salaries	934 680	1 667 020
Operating depreciation / provision	43 360	307 092
Other operating expenses	120 937	59 248
Operating expenses	2 907 667	6 150 629
Operating result	(1 334 604)	(3 243 544)
Financial income	243 395	40 386
Financial expenses	35 136	72 647
Financial result	208 259	(32 261)
Exceptional income	26 673	93 012
Exceptional expenses	437 575	19 459
Exceptional result	(410 902)	73 553
Income tax	(343 575)	(598 884)
Result of the consolidated group	(1 193 672)	(2 603 368)
Net profit or lost	(1 193 672)	(2 603 368)
Basic earnings per share	(0,32)	(0,88)

CONSOLIDATED BALANCE SHEET

ASSETS In €	30-06-2010	31-12-2009
Intangible fixed assets	534	1
Tangible fixed assets	166 200	195 949
Financial fixed assets	43 952	46 205
Total fixed assets	210 686	242 155
Inventory and Work In Progress	495 154	365 619
Operating Receivables	850 732	1 100 415
Other Receivables	823 079	1 184 212
Cash	7 575 641	1 542 164
Total current assets	9 744 606	4 192 410
Total assets	9 955 292	4 434 565

LIABILITIES In €	30-06-2010	31-12-2009
Equity share capital	3 771 471	2 971 322
Share premium	30 772 356	24 851 253
Consolidated reserves and Retained earnings	(26 369 023)	(23 765 656)
Net income	(1 193 672)	(2 603 368)
Translation adjustments	(265 956)	(6 893)
Shareholders' equity	6 715 176	1 446 658
Minority interest		
Total equity	6 715 176	1 446 658
Other share capital	366 194	366 194
Provisions	20 800	20 800
Financial debts	471 583	212 528
Trade payables	1 426 116	1 306 602
Other liabilities	955 423	1 081 783
Total debts	2 853 122	2 600 913
Total liabilities	9 955 292	4 434 565

CONSOLIDATED STATEMENT OF CASH FLOWS

CONSOLIDATED STATEMENT OF CASH FLOWS	30-06-2010	31-12-2009
In €		
Net Result	(1 193 672)	(2 603 368)
Minority interest in the result of integrated companies		
Allowance for depreciation and provisions	42 755	159 716
Write-back on depreciation and provisions		(33 000)
Gains and Losses on assets sales	(11 962)	(59 198)
Non cash subsidy		
Deferred taxes		
CASH FLOW	(1 162 879)	(2 535 850)
Change in financial expenses		
Operating change	238 377	13 008
Inventory change	(129 535)	(149 364)
Change in operating receivables	249 683	104 216
Change in trade payables	118 229	58 156
Non-operating change	(36 430)	759 512
Change in non-operating receivables	364 841	166 708
Change in non-operating payables	(108 263)	196 678
Prepaid income and expenses	(293 008)	396 126
CHANGE IN WORKING CAPITAL REQUIRED	201 947	772 520
Cash flow generated by the activity	(960 932)	(1 763 330)
Disbursement on purchase of intangible assets	(535)	
Disbursement on purchase of tangible assets	(27 483)	(30 340)
Cash inflow on disposal of intangible and tangible assets	26 673	60 000
Cashed investment grants		
Disbursement on purchase of financial assets		(3 291)
Cash inflow on disposal of intangible and tangible assets	2 253	1 147
Cash on acquisitions and transfers of subsidiaries		
Cash flow generated by investment operations	908	27 516
Capital increase or contributions	6 721 252	2 532 020
Conditional subsidy		
Paid dividends to minority interest		
Cash inflow on loans	315 900	90 000
Debt reimbursement	(57 068)	(115 305)
Cash flow generated by financial operations	6 980 084	2 506 715
CASH CHANGE	6 020 060	770 901
Impact of exchange rates changes	13 194	(2 965)
OPENING CASH	1 542 032	773 998
CLOSING CASH	7 575 286	1 542 032

The consolidated and mother company (SA – France) financial statements were dressed/booked/established by KPMG.
The financial statements of American subsidiary (INC – USA) were established by PRAMEX.
The half-year financial statements are not certified.